ADA 2022 – Move over Mounjaro?
Lilly believes it has two promising new molecules for diabetes and obesity. But which to choose – and might toxicity yet scupper one or both?
Asco 2022 – Abbvie goes back to basics with navitoclax
Abbvie’s decades-old work into Bcl-2 inhibition gave rise to Venclexta, but the group has gone back to studying a Venclexta predecessor compound.
Turning Point and Libtayo steal some pre-Asco thunder
On the eve of Asco two deals show that the current biotech market malaise might be focusing some chief executives’ minds.
Abbvie to become the biggest of pharmas in 2028
New extended consensus forecasts from Evaluate Pharma show Roche edged out of first place by Abbvie as new blood replaces Humira.
The patent winter is coming
Biopharma is approaching the most painful period of patent loss for at least 30 years. Is M&A an answer?
